Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19

Overseen by Christine M Bojanowski, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Generon (Shanghai) Corporation Ltd.

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial tests a new medicine called F-652 in adults with serious COVID-19 symptoms. It aims to see if F-652 can help these patients recover faster and reduce the severity of their illness. The medicine is given through an IV infusion.

Research Team

Christine M Bojanowski, MD

Principal Investigator

Tulane University

Eligibility Criteria

Inclusion Criteria

Willing to provide informed consent and able to comply with protocol requirements

18 years or older

Has a COVID-19 diagnosis confirmed by PCR

Treatment Details

Interventions

• F-652 (Immunomodulator)
• Placebo (Other)

Participant Groups

Group I: F-652 Experimental Treatment 1 Intervention

Patient receives standard care plus F-652

Group II: Placebo Placebo Group 1 Intervention

Patient receives standard care plus placebo

Who Is Running the Clinical Trial?

Generon (Shanghai) Corporation Ltd.

Lead Sponsor

Trials

10

Recruited

1,200+

EVIVE Biotechnology

Lead Sponsor

Trials

11

Recruited

1,200+